Epidemiology and Outcomes

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort

Manuel Francisco Ugarte-Gil, Rocio Violeta Gamboa-Cardenas, Cristina Reátegui-Sokolova, Victor Román Pimentel-Quiroz, Paola Zeña-Huancas, Claudia Elera-Fitzcarrald, Samira Garcia-Hirsh, Luciana Gil, Cesar Augusto Pastor-Asurza, Zoila Rodriguez-Bellido, Joan Merrill, Anca D Askanase, Graciela Alarcon, Risto Alfredo Perich-Campos

10.1136/lupus-2020-000419

October 12, 2020

Cutaneous vasculitis in SLE

Romy Kallas, Daniel Goldman, Michelle A Petri

10.1136/lupus-2020-000411

September 22, 2020

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations

Aurore Meyer, Aurélien Guffroy, Gilles Blaison, Yannick Dieudonne, Zahir Amoura, Bernard Bonnotte, Christoph Fiehn, Pierre Kieffer, Hannes Martin Lorenz, Nadine Magy-Bertrand, François Maurier, Jean-Louis Pennaforte, Hans-Hartmut Peter, Andreas Schwarting, Jean Sibilia, Laurent Arnaud, Thierry Martin, Reinhard Edmund Voll, Anne-Sophie Korganow, and the LBBR/Rarenet group, Z Amoura, L Arnaud, G Blaison, B Bonnotte, E Chatelus, E Ciobanu, F Duchene, JP Faller, A Gorse, JE Gottenberg, O Hinschberger, F Jaeger, P Kieffer, M Kilifa, N Magy-Bertrand, T Martin, L Martzolff, F Maurier, A Meyer, J-L Pasquali, J-L Pennaforte, V Poindron, S Revuz, M Samson, J Sibilia, C Sordet, A Theulin, D Wahl, JC Weber, M Bartsch, N Bartholomä, C Fiehn, S Finzel, A Funkert, M Hausberg, H Lorenz, R Max, H-H Peter, M Rizzi, A Schwarting, J Thiel, N Venhoff, R Voll

10.1136/lupus-2020-000399

July 2, 2020

Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease

Dionysis S Nikolopoulos, Myrto Kostopoulou, Antigoni Pieta, Sofia Flouda, Katerina Chavatza, Aggelos Banos, John Boletis, Pelagia Katsimbri, Dimitrios T Boumpas, Antonis Fanouriakis

10.1136/lupus-2020-000394

June 29, 2020

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review

Vibeke Strand, Lee S Simon, Alexa Simon Meara, Zahi Touma

10.1136/lupus-2019-000373

June 25, 2020

Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE

Ola Nived, Ragnar Freyr Ingvarsson, Anna Jöud, Petrus Linge, Helena Tydén, Andreas Jönsen, Anders A Bengtsson

10.1136/lupus-2020-000398

June 24, 2020

Overcoming barriers to recruitment and retention of African–American women with SLE in behavioural interventions: lessons learnt from the WELL study

Cristina Drenkard, Kirk Easley, Gaobin Bao, Charmayne Dunlop-Thomas, S Sam Lim, Teresa Brady

10.1136/lupus-2020-000391

June 11, 2020

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus

Rachel Koelmeyer, Hieu Tri Nim, Mandana Nikpour, Ying B Sun, Amy Kao, Oliver Guenther, Eric Morand, Alberta Hoi

10.1136/lupus-2019-000372

May 27, 2020

Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus

Ileana Vázquez-Otero, Nicolle Medina-Cintrón, Mariangelí Arroyo-Ávila, Lorena González-Sepúlveda, Luis M Vilá

10.1136/lupus-2020-000395

May 19, 2020

Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA

Christopher F Bell, Julie Priest, Marni Stott-Miller, Hong Kan, Justyna Amelio, Xue Song, Brendan Limone, Virginia Noxon, Karen H Costenbader

10.1136/lupus-2019-000357

March 26, 2020